Cerebrospinal fluid (CSF) plays a crucial role in Alzheimer's Disease (AD) and dementia research. In AD, abnormal accumulation of proteins like amyloid-beta and tau in the brain leads to cognitive decline. CSF acts as a conduit for these biomarkers, reflecting changes in their levels. Researchers use CSF analysis to detect early signs of AD by measuring amyloid-beta and tau proteins. Elevated levels of tau and decreased amyloid-beta in CSF are indicative of neurodegeneration and correlate with cognitive impairment. This fluid also helps in drug development, as changes in biomarkers can indicate treatment effectiveness. Understanding CSF dynamics enhances diagnostic accuracy and provides insights into disease progression, offering hope for earlier interventions and improved management strategies for AD and related dementias.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China